Medipattern Receives U.S. Patent for Multi-Modality Detection of Lesions Furthering Its Technology
November 03 2011 - 7:00AM
Marketwired
Attention: Business/Financial Editors
The Medipattern Corporation ("Medipattern") (TSX VENTURE:MKI), a
pioneer in the development of medical imaging software solutions
that help medical practitioners to better understand lesions and
critical anatomy, is pleased to announced that it received United
States Patent number 8,014,576 for a "method and system of
computer-aided quantitative and qualitative analysis of medical
images." The patent relates to the field of computer-aided analysis
of medical images and detection of suspicious abnormalities. It
defines a method and system for processing medical images obtained
from multiple modalities, including analysis of kinetics as well as
morphological features and automated detection of abnormalities,
and analysis of medical images from multiple modalities.
The patent extends the core technology for Medipattern embodied
in its Cadenza(TM) Platform to analyze and characterize medical
images. Medipattern's previous patent, number 7,783,094, addressed
computer aided detection in medical images which are analyzed, to
extract and identify a set of features in the image relevant to a
diagnosis. This new patent also covers the combined use of
morphological and kinetic features to compute a consolidated
assessment of a possible lesion detected in medical imaging. Though
the technology was primarily invented for the use of combining the
various image modalities in breast imaging (x-ray based
mammography, Ultrasound, Computed Tomography (CT), Positron
Emission Tomography (PET/CT), Magnetic Resonance Imaging (MRI), MR
Spectroscopy (MRS) and Nuclear Imaging, the patented algorithm can
be used in other medical imaging applications where the combination
of various modalities can lead to a better understanding of the
abnormality as would be the case for vascular imaging studies that
use US, CT Angiography and MR Angiography to diagnose patients. The
inventors are Jeffrey Collins, President and CEO of Medipattern,
Frederic Lachmann, Ph. D, Chief Technology Officer of Medipattern,
Karen Saghatelyan, and Sandra Stapleton. The technology is under
review for patent protection in several other countries
globally.
"The new patent solidifies Medipattern's position as a globally
recognized leading edge developer of medical imaging analysis
tools. We congratulate the entire team at Medipattern for their
accomplishment and their contribution to the furtherance of medical
science," commented Janet Sterritt, VP of Business Strategy for
Medipattern. "Cadenza is the basis for our B-CAD®, B-CADmri(TM) and
Visualize:Vascular(TM) products. B-CADmri technology was
subsequently exclusively licensed to Sentinelle Medical, now a
Hologic company. The combined capabilities of detection,
identification, characterization, rendering and visualization form
a medical image analysis tool set that is unique to Medipattern.
The combination of being able to identify the lesion in pictures,
characterize it in words, measure it analytically and assess its
level is highly valued in being able to fully assist physicians in
more readily assessing the extent of lesions. Medipattern also adds
3D rendering with our new vascular product line so that the
physician can visualize critical anatomy, providing a new
perspective."
2011 Upcoming Events
Veith 38th Annual Symposium, Nov. 16 to 20 with partner Navix Diagnostix
RSNA 2011, Nov. 27 - Dec. 2 with partners TomTec and PenRad
About The Medipattern Corporation:
Medipattern® is a pioneer in the development of imaging software
solutions that help medical practitioners to better understand
lesions and critical anatomy. Medipattern uses its Cadenza(TM)
technology to process images, finding the salient region of
interest and presenting them in 2D and 3D formats that enhance the
reader's perception. For more information, please visit the
Company's website: www.medipattern.com.
Medipattern® is a registered mark of The Medipattern
Corporation. Visualize:Vascular(TM) is a trademark of the
Medipattern Corporation.
Forward-looking statements
This document contains forward-looking statements relating to
Medipattern's performance, operations, or business environment.
These statements are based on what we believe are reasonable
assumptions given currently available information and our
understanding of Medipattern's current activities. We have tried,
whenever possible, to identify these forward-looking statements
using words such as "anticipates," "believes," "estimates,"
"expects," "plans," "intends," "potential", and similar
expressions. Forward-looking statements are not guarantees of
future performance and involve risks and uncertainties that are
difficult to predict or control. A number of factors could cause
actual outcomes and results to differ materially from those
expressed in forward-looking statements. These factors include but
are not limited to those set forth in the Company's corporate
filings (posted at www.sedar.com). In addition, these
forward-looking statements relate to the date on which they are
made. The Company disclaims any intention or obligation to update
or revise any forward-looking statements for any reason. Readers
should not rely on forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contacts: The Medipattern Corporation Jeff Collins CEO (416)
744-0009 ext. 224jcollins@medipattern.com Spinnaker Capital Markets
Inc. Kevin O'Connor (416) 962-3300 ext.
226ko@spinnakercmi.comwww.medipattern.com
The Medipattern Corp. (TSXV:MKI)
Historical Stock Chart
From Jun 2024 to Jul 2024
The Medipattern Corp. (TSXV:MKI)
Historical Stock Chart
From Jul 2023 to Jul 2024